Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT05607849 Not yet recruiting - Breast Cancer Clinical Trials

Breast Cancer Screening Uptake: a Randomized Controlled Trial Assessing the Effect of a Decisional Aid

DEDICACES2
Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Shared decision-making for organised breast cancer screening could be improved by fostering interaction and exchanges of information between women and GPs, for instance by including an assistance tool in the dispatch of the invitation letter for Organised Screening (OS) for breast cancer. In 2018 the national cancer Institute funded the development of a decisional aid (DA) on the theme of whether or not to take part in breast cancer screening, specific to the French setting. It is the website Discutons-mammo.fr DEDICACES project 1. DEDICACES 2 is a pragmatic, non-inferiority, population-based trial with a cluster design. The aim is to assess the impact of the dispatch of a leaflet informing women of the existence of the DA Discutons-mammo.fr on the uptake by eligible women of breast cancer screening in an organised setting in usual practical conditions and in the general population

NCT ID: NCT05603013 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

Start date: October 30, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, Phase II investigator-initiated trial of vinorelbine metronomic chemotherapy combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for treatment of advanced refractory non-small cell lung cancer and breast cancer.

NCT ID: NCT05600153 Not yet recruiting - Clinical trials for Breast Reconstruction

Axillary Versus Primary Breast Approach for Second-stage Breast Reconstruction

AvBSR
Start date: December 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the safety of axillary or primary breast approach for second-stage operation in expander-implant breast reconstruction for breast cancer patients. The main question it aims to answer are: 1. if the wound related events, including wound dehiscence, infection, delayed healing is significant less often in patients receiving second stage operation via axillary approach compared with primary breast approach; 2. if the aesthetic outcome is comparable between patients receiving different approach for second stage operation. To answer these questions, the breast cancer patients have received nipple-sparing or skin-sparing mastectomy and had breast tissue expander insertion via breast incision, will be prospectively recruited, and randomized into two groups while receiving implant exchange operation: (1) operate via axillary incision; (2) operate via primary breast incision.

NCT ID: NCT05586841 Not yet recruiting - Clinical trials for HR+/HER2- Advanced Breast Cancer

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

Start date: November 1, 2022
Phase: Phase 1
Study type: Interventional

A phase 1B study to explore the maximum tolerated dose (MTD) of dalpiciclib + chidamide in HR+/HER2- advanced breast cancer after the failure of CDK4/6 inhibitor therapy

NCT ID: NCT05586659 Not yet recruiting - Breast Cancer Clinical Trials

Epidemiology of TNBC in Asyut Clinical Oncology Department

Start date: November 1, 2022
Phase:
Study type: Observational

Epidemiological Study about behavior of TNBC in Clinical oncology department in 8 y in Asyut university hospital

NCT ID: NCT05585476 Not yet recruiting - Clinical trials for Breast Cancer Female

A Laser and Topical Treatment Combination in the Vulvo-vaginal Atrophy Management in Breast Cancer Patients.

Start date: June 2024
Phase: N/A
Study type: Interventional

The genito-urinary syndrome of menopause severely affects patients with a history of gynecological cancer, especially those diagnosed with breast cancer. At the present time, we do not have solid scientific evidence on treatments that can be effective and safe to address this pathology. Based on the above, we have developed our working hypothesis where it is postulated that the microfractionated laser treatment of C02, in conjunction with topical regenerative treatment, constitute an effective alternative in the management of vulvo-vaginal atrophy in oncological patients who have contraindicated hormonal treatments.

NCT ID: NCT05578053 Not yet recruiting - Breast Cancer Clinical Trials

Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

Start date: October 26, 2022
Phase:
Study type: Observational

This study is a multi-center, observational, real-world study. We planned to recruit 420 HR+ locally advanced or metastatic breast cancer patients who had received or had not received prior systemic therapy. All patients included in the analysis were receiving or planning to receive dalpiciclib-containing regimens without restrictions, completely following the physician 's clinical choice, to assess the efficacy and safety of dalpiciclib-containing regimens.

NCT ID: NCT05577923 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

Start date: November 1, 2022
Phase: Phase 2
Study type: Interventional

This study is a prospective, single-arm, phase II clinical study for patients with ER+/HER2+ advanced breast cancer.

NCT ID: NCT05577442 Not yet recruiting - Clinical trials for Breast Neoplasm Female

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

Start date: October 20, 2022
Phase: Phase 2
Study type: Interventional

This study investigates the efficacy and safety of trastuzumab, pyrotinib combined with dalpiciclib and endocrine therapy for patients with advanced HR+/HER2+ brest cancer, providing more possible effective regimens for the survival benefit of these patients in clinical practice.

NCT ID: NCT05567601 Not yet recruiting - Multiple Myeloma Clinical Trials

Doxil/Caelyx BE Study

Start date: November 30, 2023
Phase: Phase 1
Study type: Interventional

The aim of this study is to demonstrate the bioequivalence of DOXIL/CAELYX, 40 mg/m2 (IV infusion over 90 minutes) between two manufacturing facilities. According to the Food and Drug Administration (FDA), two products are considered to be bioequivalent when they are equal in the rate and extent to which the active pharmaceutical ingredient (API) becomes available at the site(s) of drug action. Any abnormalities of the safety endpoints (Clinical Laboratory Test, Electrocardiogram, Left Ventricular Ejection Fraction, Physical Examination) will be captured as Adverse Events.